Trial reportThe Journal of infectious diseases2001
Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS.
Trial report in The Journal of infectious diseases, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 113 citations in OpenAlex.
- Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.The Journal of clinical investigation · 2002Trial
- Cross-Subtype Detection of HIV-1 Capsid p24 Antigen Using a Sensitive Europium Nanoparticle Assay.AIDS research and human retroviruses · 2019Article
- Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort.PLoS medicine · 2018Article
- Naturally occurring Vpr inhibitors from medicinal plants of Myanmar.Journal of natural medicines · 2017Review
- Treatment outcomes in a rural HIV clinic in South Africa: Implications for health care.Southern African journal of HIV medicine · 2016Article
- Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia.Journal of medical virology · 2015Article
- HIV-1 and HIV-2 differentially mature plasmacytoid dendritic cells into IFN-producing cells or APCs.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control group.International journal of STD & AIDS · 2012Article
- Protein kinase Ctheta is a specific target for inhibition of the HIV type 1 replication in CD4+ T lymphocytes.The Journal of biological chemistry · 2011Article
- Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort.PloS one · 2011Article
- Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection.PloS one · 2011Article
- Low prevalence of varicella zoster virus and herpes simplex virus type 2 in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy.Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics · 2010Article
- Functional properties and epitope characteristics of T-cells recognizing natural HIV-1 variants.Vaccine · 2009Article
- Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells.Journal of virology · 2009Article
- Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort.European journal of medical research · 2009Article
- Identifying acute HIV infection in Rhode Island.Medicine and health, Rhode Island · 2009Article
- HIV dynamics in seminal plasma during primary HIV infection.AIDS research and human retroviruses · 2008Article
- Resisting immune exhaustion in HIV-1 infection.PLoS medicine · 2008Article
- Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection.Journal of virology · 2007Article
- Primary human immunodeficiency virus type 1 infection.Current HIV/AIDS reports · 2005Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
Immunologic data supporting immediate antiretroviral therapy in primary human immunodeficiency virus type 1 (HIV-1) infection are emerging; however, clinical benefit has not been demonstrated. The clinical and virologic course of 47 patients who were enrolled from September 1993 through June 1996 and who were not initially treated with potent therapy was compared with the course of 20 patients who immediately began therapy with zidovudine, lamivudine, and indinavir. Demographic and baseline laboratory data were comparable. During 78 weeks of follow-up, the early-treatment cohort showed a reduced frequency of opportunistic infections (5% vs. 21.3%; relative risk, 0.11; P=.02), less frequent progression to AIDS (13% vs. 0%), and significantly less frequent nonopportunistic mucocutaneous disorders and respiratory infections (P<.01). Plasma HIV-1 RNA levels were <50 copies/mL in all patients who continued therapy; however, after 9--12 months, HIV-1 remained detectable in latently infected CD4(+) T cells and in lymph node mononuclear cells. Combination antiretroviral therapy during primary HIV-1 infection demonstrated a decreased frequency of minor opportunistic infections, mucocutaneous disorders, and respiratory infections and reduced progression to AIDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.